tailieunhanh - báo cáo khoa học: "Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway | Chen et al. Journal of Experimental Clinical Cancer Research 2011 30 17 http content 30 1 17 Journal of Experimental Clinical Cancer Research RESEARCH Open Access Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K Akt pathway 1 f 1 f r z 1 2 1 3 3 Wei-Sheng Chen Jun-Na Hou Yu-Biao Guo Hui-Ling Yang Can-Mao Xie Yong-Cheng Lin Zhi-Gang She Abstract Background Bostrycin is a novel compound isolated from marine fungi that inhibits proliferation of many cancer cells. However the inhibitory effect of bostrycin on lung cancers has not been reported. This study is to investigate the inhibitory effects and mechanism of bostrycin on human lung cancer cells in vitro. Methods We used MTT assay flow cytometry microarray real time PCR and Western blotting to detect the effect of bostrycin on A549 human pulmonary adenocarcinoma cells. Results We showed a significant inhibition of cell proliferation and induction of apoptosis in bostrycin-treated lung adenocarcinoma cells. Bostrycin treatment caused cell cycle arrest in the G0 G1 phase. We also found the upregulation of microRNA-638 and microRNA-923 in bostrycin-treated cells. further we found the downregulation of p110a and p-Akt PKB proteins and increased activity of p27 protein after bostrycin treatment in A549 cells. Conclusions Our study indicated that bostrycin had a significant inhibitory effect on proliferation of A549 cells. It is possible that upregulation of microRNA-638 and microRNA-923 and downregulaton of the PI3K AKT pathway proteins played a role in induction of cell cycle arrest and apoptosis in bostrycin-treated cells. Background Lung cancer is the most common type of cancer worldwide. Despite recent advances in surgical techniques and chemotherapy radiotherapy strategies the long-term survival rates remain poor. There is therefore an urgent need to develop new therapeutic strategies in order to significantly improve the prognosis in lung cancer .